References
- Setter SM, Iltz JL, Thams J, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Therapeut 2003;25:2991-3026
- Bloomgarden ZT. Diabetes treatment. Diabetes Care 2009;32:e25-30
- Scheen AJ, Lefebvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998;55:225-36
- Bell DS. Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med 2004;116:23S-29S
- Bermudex V, Finol F, Parra N, et al. PPAR-gamma agonists and their role in type 2 diabetes mellitus management. Am J Therapeut 2010;17:274-83
- Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Exper Opin Investig Drugs 2006;15:243-50
- Elte JW, Blickle JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med 2007;18:18-25
- Kim BY, Ahn JB, Lee HW, et al. Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione. Eur J Med Chem 2004;39:433-47
- Lee HW, Kim BY, Ahn JB, et al. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem 2005;40:862-74
- Kim JW, Kim J, Yi S, et al. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a PPAR γ agonist, in healthy male Korean subjects. Clin Therapeut 2011;33:1819-30
- Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Therapeut 2000;22:1395-409
- Prato SD, Volpe L. Rosiglitazone plus metformin: combination therapy for type 2 diabetes. Expert Opin Pharmacother 2004;5:1411-22
- Guideline for Good Clinical Practice Efficacy Guidelines. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Available at: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html [Last accessed 28 December 2011]
- Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html [Last accessed 28 December 2011]
- Shin H-S, Seo HB, Shin JS. Quantitative determination of CKD-501 by high turbulence liquid chromatography – tandem mass spectrometry in human plasma and urine. 17th International Mass Spectrometry Conference. Prague, Czech Repulic: IMSC 2006;2006:MoP-105
- Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. 4th edn. Sweden: Swedish Pharmaceutical Press, 2007
- Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72
- Zhang L, Reynolds KS, Zhao P, et al. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol 2010;243:134-45
- US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (FDA, CDER). Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf [Last accessed 28 December 2011]
- Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-46
- Graham GG, Punt J, Arora M, et al. Clinical Pharmacokinetics. Clinical pharmacokinetics of metformin. 2011;50:81-98
- GLUCOPHAGE (metformin hydrochloride tablets). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf [Last accessed 28 December 2011]